Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321203 | 0.87 | PKM (0.47) | ACHEMEN1KMT2APKML3MBTL1 | |
| SCHEMBL3322725 | 0.84 | MEN1 (0.50) | ACHEMEN1KMT2APKML3MBTL1 | |
| SCHEMBL3322116 | 0.74 | SCN1A (0.40) | ACHEPKML3MBTL1 | |
| SCHEMBL3321651 | 0.74 | PKM (0.61) | ACHEMEN1KMT2APKML3MBTL1 | |
| SCHEMBL3323699 | 0.72 | DRD2 (0.62) | ACHEMEN1KMT2APKML3MBTL1 | |
| SCHEMBL13439213 | 0.72 | CA2 (0.42) | MEN1KMT2APKML3MBTL1LMNA | |
| SCHEMBL13361813 | 0.71 | DRD2 (0.53) | ACHEMEN1KMT2APKML3MBTL1 | |
| SCHEMBL3323191 | 0.70 | DRD2 (0.52) | ACHEMEN1KMT2APKML3MBTL1 | |
| SCHEMBL21101096 | 0.70 | BCHE (0.62) | ACHESLC6A4SLC6A3 | |
| SCHEMBL8825359 | 0.67 | ACHE (0.60) | ACHESLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | claimed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | claimed |
| EP-2148879-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | claimed |
| WO-2008128996-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | claimed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-2148879-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128996-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | GRIN2A, DRD2, GRIN2C | ACHE 776/4885MEN1 4005/4885KMT2A 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.